Table 2.
Multiple analysis of baPWV and plaque presence
| baPWV, m/s | N | Plaque presence, N (%) | Nonadjusted | Adjusted | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |||
| Continuous | 13,554 | 5661 (41.8) | 1.12 (1.10, 1.13) | <0.001 | 1.05 (1.04, 1.07) | <0.001 |
| Quartile | ||||||
| Q1 (<14.81) | 3389 | 1044 (30.8) | Ref. | Ref. | ||
| Q2 (14.81 ≤ 16.73) | 3378 | 1240 (36.7) | 1.30 (1.18, 1.44) | <0.001 | 1.06 (0.95, 1.19) | 0.317 |
| Q3 (16.73 ≤ 19.06) | 3384 | 1547 (45.7) | 1.89 (1.71, 2.09) | <0.001 | 1.32 (1.17, 1.49) | <0.001 |
| Q4 (≥19.06) | 3403 | 1830 (53.8) | 2.61 (2.37, 2.89) | <0.001 | 1.49 (1.31, 1.70) | <0.001 |
| P for trend | <0.001 | <0.001 | ||||
Adjusted for age, gender, BMI, alcohol consumption status, smoking status, SBP and DBP at baseline, TC, HDL-c; FPG, eGFR, homocysteine, folate, TG, glucose-lowering medication, antihypertensive medication, study center, and folic treatment group
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, FPG fasting plasma glucose, eGFR estimated glomerular filtration rate, TG triglyceride